Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biofrontera (BFRI) Net Margin (2020 - 2025)

Biofrontera has reported Net Margin over the past 6 years, most recently at 32.98% for Q4 2025.

  • For Q4 2025, Net Margin rose 4410.0% year-over-year to 32.98%; the TTM value through Dec 2025 reached 25.26%, up 2232.0%, while the annual FY2025 figure was 25.26%, 2232.0% up from the prior year.
  • Net Margin for Q4 2025 was 32.98% at Biofrontera, up from 95.15% in the prior quarter.
  • Over five years, Net Margin peaked at 57.03% in Q1 2022 and troughed at 369.45% in Q3 2021.
  • A 5-year average of 69.23% and a median of 60.95% in 2021 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: crashed -27766bps in 2021 and later surged 31008bps in 2022.
  • Year by year, Net Margin stood at 158.21% in 2021, then surged by 83bps to 27.45% in 2022, then surged by 221bps to 33.28% in 2023, then plummeted by -133bps to 11.12% in 2024, then soared by 397bps to 32.98% in 2025.
  • Business Quant data shows Net Margin for BFRI at 32.98% in Q4 2025, 95.15% in Q3 2025, and 58.96% in Q2 2025.